Julie Kobie

Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC

Roy S. Herbst, Edward B. Garon, Dong‐Wan Kim et al. · Journal of Thoracic Oncology · 2021 · 286 citations · Full text

Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407

Luis Paz‐Ares, Corey J. Langer, Silvia Novello et al. · Annals of Oncology · 2019 · 103 citations

Medicine, Pharmacology, Metastatic Nsclc +7

Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials

Roy S. Herbst, G. Lopes, D.M. Kowalski et al. · Annals of Oncology · 2019 · 97 citations

Medicine, Pembrolizumab Monotherapy, Immunology +10

LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in Keynote-042

Roy S. Herbst, Gilberto Lopes, Dariusz M. Kowalski et al. · Annals of Oncology · 2019 · 91 citations · Full text

Immunology, Lba4 Association, Immune Checkpoint Inhibitor +7

OA04.06 Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC

Marina Chiara Garassino, Delvys Rodríguez‐Abreu, Shirish M. Gadgeel et al. · Journal of Thoracic Oncology · 2019 · 90 citations · Full text

Medicine, Immunology, Clinical Trials +8